Sling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023
– Treatment with linsitinib in a clinically relevant mouse model demonstrated a significant reduction in autoimmune response and classical Thyroid Eye Disease (TED) symptoms, independent of TED severity – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of active, moderate to severe TED – ANN ARBOR, Mich., June 17, 2023 /PRNewswire/ — Sling … Read more